Abstract Title:

SYNERGISM OF CURCUMIN AND CYTARABINE IN THE DOWN REGULATION OF MULTI DRUGRESISTANCE GENES IN ACUTE MYELOID LEUKEMIA.

Abstract Source:

Anticancer Agents Med Chem. 2015 Aug 17. Epub 2015 Aug 17. PMID: 26278546

Abstract Author(s):

Krupa Shah, Sheefa Mirza, Urja Desai, Nayan Jain, Rakesh Rawal

Article Affiliation:

Krupa Shah

Abstract:

BACKGROUND: The aim of the study was to find a role of Curcumin from natural source to overcome drug resistance as well as to reduce cytotoxicity profile of the drug in Acute Myeloid Leukemia patients.

MATERIAL AND METHODS: Primary leukemic cells were obtained from AML patient's bone marrow. These cells were then exposed to different concentration of cytarabine and curcumin to find out IC50 values and also its effect on MDR genes like MDR1, BCRP, LRP and FLT3 by RT-PCR method.

RESULT & CONCLUSION: Our results suggested that curcumin down regulates MDR genes. Gene expression was decreased by 35.75, 31.30, 27.97 % for MDR1, LRP, BCRP respectively. In FLT3 it was 65.86 % for wild type and 31.79 % for FLT3-ITD. In addition to this, curcumin also has shown anti-proliferative effect as well as synergistic effect in combination with Cytarabine on primary leukemic cells. Thus, we can conclude that curcumin can be used as MDR modulator as well as chemosensitizer in combination with cytarabine, standard chemotherapeutic drug, to reduce the cytotoxicity profile as IC50 value decreases when treated in combination.

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.